NCT05198804 A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian Cancer Status COMPLETED Phase PHASE1/PHASE2
NCT05194735 Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors Status TERMINATED Phase PHASE1/PHASE2
NCT05187208 PARP Inhibitor Oral Maintenance in Low-Risk Ovarian Cancer Status NOT_YET_RECRUITING Phase PHASE4
NCT05185947 Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis Status COMPLETED Phase PHASE2
NCT05183984 Niraparib With beVAcizumab After Complete cytoreductioN in Patients With ovArian Cancer Status RECRUITING Phase PHASE2
NCT05179824 Tempus Priority Study: A Pan-tumor Observational Study Status ACTIVE_NOT_RECRUITING Phase N/A
NCT05175326 Study on the Consistency Evaluation of Organoids Used in the Clinical Treatment of Ovarian Cancer With Anti-tumor Drugs Status UNKNOWN Phase N/A
NCT05170594 A Study of Bevacizumab Combined With Fluzoparib/Chemotherapy or Fluzoparib in the Treatment of Ovarian Cancer Status UNKNOWN Phase PHASE2
NCT05156892 Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Status ACTIVE_NOT_RECRUITING Phase PHASE1
NCT05145569 Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic Advanced Stage Ovarian Cancer Status WITHDRAWN Phase PHASE2
NCT05132868 Assessments of Genetic Counseling Augmented With an Educational Video or Pamphlet Versus Traditional Counseling Status COMPLETED Phase NA
NCT05124743 HLA Typing & Tumor Neoantigen Identification for Phase I/II Study of Autologous TCR-T Cells in Subjects With Solid Tumors Status TERMINATED Phase N/A
NCT05123807 Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study) Status RECRUITING Phase PHASE2
NCT05123482 A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies Status RECRUITING Phase PHASE1/PHASE2
NCT05116189 Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). Status ACTIVE_NOT_RECRUITING Phase PHASE3